Morgan Stanley Upgrades Cigna On Humira Prospects Cigna Corp (NYSE: CI) is poised to benefit from the launch of bioequivalent Humira in July 2023, according to Morgan Stanley. Benzinga · Jun 22, 2022
Federal regulators probe Cigna’s pharmacy benefit manager, CVS Caremark, and others. What are they investigating? Express Scripts, the pharmacy benefit manager that Cigna Corp. bought in 2018, is being investigated by the Federal Trade Commission for what regulators claim is influence over drug prices wielded by pharmacy benefit managers and transparent business practices. Tribune News Service · Jun 10, 2022
Eli Lilly, Novo Nordisk, Sanofi Accused Of Artificially Raising Insulin Prices Arkansas has accused Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Sanofi SA (NASDAQ:SNY), and three of the largest pharmacy benefit managers (PBMs) of artificially driving up insulin prices. The complaint, filed by Arkansas Attorney General Leslie Rutledge, alleges the defendants devised a scheme in which the Big Pharmas would "artificially and willingly raise their… Benzinga · May 13, 2022
Here's Why RBC Capital Raised Price Target On Cigna Cigna Corp (NYSE:CI) posted 1Q22 adjusted EPS well above expectations on enterprise-wide growth, with a particularly solid performance in specialty pharmacy and better than expected MCR on lower testing and treatment costs. The company raised FY22 guidance on 1Q outperformance. The analysts raised the price target to $272 from $235, with a Sector Perform rating. … Benzinga · May 9, 2022
Cigna Q1 Earnings Beat Expectations, Lifts FY22 Guidance Cigna Corp (NYSE:CI) reports Q1 total revenues of $44.12 billion, +7.6% Y/Y, ahead of the consensus of $43.41 billion. Cigna brought in $1.18 billion in earnings, up from $1.16 billion a year ago. Q1 adjusted EPS reached $6.01 compared with $4.73 a year ago, beating the consensus of $5.18. By the end of… Benzinga · May 6, 2022
Cigna Shares Fall As FY22 Guidance Falls Short Of Consensus; Q4 Profit Of $1.1B Cigna Corp (NYSE: CI) reports Benzinga · Feb 3, 2022